Pritesh Desai
Overview
Explore the profile of Pritesh Desai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
583
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bullock C, Wang L, Ware B, Wagoner N, Ohara R, Liu T, et al.
mBio
. 2024 Nov;
15(12):e0293024.
PMID: 39535221
Ross River virus (RRV) and other alphaviruses cause chronic musculoskeletal syndromes that are associated with viral persistence, which suggests deficits in immune clearance mechanisms, including CD8 T-cell responses. Here, we...
2.
Ou F, Liu T, Desai P, Ferris S, Kim S, Shen H, et al.
Nat Immunol
. 2024 Oct;
25(11):2043-2056.
PMID: 39375550
Autoactivation of lineage-determining transcription factors mediates bistable expression, generating distinct cell phenotypes essential for complex body plans. Classical type 1 dendritic cell (cDC1) and type 2 dendritic cell (cDC2) subsets...
3.
Janova H, Zhao F, Desai P, Mack M, Thackray L, Stappenbeck T, et al.
J Clin Invest
. 2024 Aug;
134(21).
PMID: 39207863
Intestinal dysmotility syndromes have been epidemiologically associated with several antecedent bacterial and viral infections. To model this phenotype, we previously infected mice with the neurotropic flavivirus West Nile virus (WNV)...
4.
Ying B, Liang C, Desai P, Scheaffer S, Elbashir S, Edwards D, et al.
J Virol
. 2024 Aug;
98(9):e0057424.
PMID: 39194250
Boosting with mRNA vaccines encoding variant-matched spike proteins has been implemented to mitigate their reduced efficacy against emerging SARS-CoV-2 variants. Nonetheless, in humans, it remains unclear whether boosting in the...
5.
Desai P, Karl C, Ying B, Liang C, Garcia-Salum T, Santana A, et al.
Sci Transl Med
. 2024 Aug;
16(761):eado1941.
PMID: 39167662
Although vaccines have reduced the burden of COVID-19, their efficacy in helminth infection-endemic areas is not well characterized. We evaluated the impact of infection by (Hpb), a murine intestinal roundworm,...
6.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
Nat Immunol
. 2024 Feb;
25(3):578.
PMID: 38360936
No abstract available.
7.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
Nat Immunol
. 2024 Feb;
25(3):537-551.
PMID: 38337035
A nasally delivered chimpanzee adenoviral-vectored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (ChAd-SARS-CoV-2-S) is currently used in India (iNCOVACC). Here, we update this vaccine by creating ChAd-SARS-CoV-2-BA.5-S, which encodes...
8.
Desai P, Karl C, Ying B, Liang C, Garcia-Salum T, Santana A, et al.
bioRxiv
. 2024 Jan;
PMID: 38293221
Although vaccines have reduced COVID-19 disease burden, their efficacy in helminth infection endemic areas is not well characterized. We evaluated the impact of infection by (Hpb), a murine intestinal hookworm,...
9.
Zimmerman O, Doss A, Ying B, Liang C, Mackin S, Davis-Adams H, et al.
JCI Insight
. 2024 Jan;
9(3).
PMID: 38175703
Immunoglobulin (IG) replacement products are used routinely in patients with immune deficiency and other immune dysregulation disorders who have poor responses to vaccination and require passive immunity conferred by commercial...
10.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
bioRxiv
. 2023 May;
PMID: 37205450
We previously described a nasally delivered monovalent adenoviral-vectored SARS-CoV-2 vaccine (ChAd-SARS-CoV-2-S, targeting Wuhan-1 spike [S]; iNCOVACC) that is currently used in India as a primary or booster immunization. Here, we...